OPUS PHARMACEUTICALS LIMITED

What OPUS PHARMACEUTICALS LIMITED does

CSPC Pharmaceutical Group Limited (HKEX: 1093) is a vertically integrated Chinese pharmaceutical company founded in 1997 (with origins tracing to 1938) and headquartered in Shijiazhuang, Hebei Province. The company operates across the full pharmaceutical value chain — research, manufacturing, and commercialization — spanning small molecule drugs, macromolecule biologics, novel preparations, and advanced drug delivery systems. CSPC serves global markets across 6 continents and 114 countries/regions through regional sales headquarters in the Americas (Ontario, Princeton), Europe (Hamburg), and South America (São Paulo).

The company's product portfolio includes APIs (penicillins, cephalosporins, vitamin C/B12, caffeine), generic formulations (azithromycin, penems, cephalosporin injections), and proprietary innovative drugs. Flagship innovations include NBP/Butylphthalide (National Class I new drug for acute ischemic stroke, launched 2004), Duoenda (world's first mitoxantrone nano-drug liposome, 2022), and Copiktra (first PI3K selective inhibitor approved in China, 2022). Proprietary technology platforms span mRNA vaccines (SYS6006), antibody-drug conjugates (SYS6002, SYS6043), GLP-1 Fc fusion proteins (TG103, SYH9017/semaglutide), and FcRn inhibitors (batoclimab).

The business model combines direct sales to hospitals and healthcare systems in China, B2B API supply to multinational pharmaceutical companies (Merck, Bayer, Eisai, DSM), international distribution through regional offices, and an emerging licensing/royalty stream from out-licensed assets (Harbour Biomed, Flame Biosciences, AstraZeneca). With approximately 30,000 employees (including 2,000+ researchers), 10+ production bases, RMB 64 billion in total assets, and annual revenue of US$6.5 billion (2021), CSPC is ranked 25th globally in Torreya's Pharma 1000. The pipeline contains 300+ projects, with R&D investment of RMB 3.5 billion in 2021.

Name

OPUS PHARMACEUTICALS LIMITED

Legal name

CSPC PHARMACEUTICAL GROUP LIMITED

Website

https://e-cspc.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

CSPC Pharmaceutical Group is a leading Chinese pharmaceutical company that develops, manufactures, and commercializes innovative drugs, APIs, and formulations across oncology, CNS, metabolic, and infectious diseases, serving hospitals and global pharma companies in 114+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Pharmaceutical manufacturing
• Innovative drug development
• Oncology therapeutics
• Cardiovascular medicines
• Generic pharmaceuticals

Headquarters

HQ city

北京, 北京市

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products Manufacturing and Sales: CSPC generates revenue through manufacturing and selling pharmaceutical products including APIs (Active Pharmaceutical Ingredients), formulations, and finished dosage forms. The company has 10+ pharmaceutical production bases and products sold in 100+ countries and regions.
2. Licensing and Royalty Income: Revenue from exclusive license agreements including upfront payments, milestone payments, and tiered royalties based on annual net sales. Example: batoclimab licensing agreement with RMB150M upfront, up to RMB50M technology milestones, up to RMB400M development/regulatory milestones, up to US$57.5M sales milestones plus royalties.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

OPUS PHARMACEUTICALS LIMITED (operating as CSPC Pharmaceutical Group) manufactures and sells innovative and generic pharmaceutical products across oncology, cardiovascular, nervous system, anti-infectives, immunology, and metabolic disease therapeutic areas. The company operates more than 10 manufacturing bases across China with over 2,000 production lines, producing both APIs and finished formulations (injections, capsules, tablets, oral liquids, etc.). It also conducts licensing deals, in-licensing and out-licensing of pharmaceutical products and technology.

Product overview

CSPC Pharmaceutical Group is a leading Chinese pharmaceutical company integrating research, production, and marketing. The company operates across three main product categories: Core Products (antibiotics, cardiovascular, and CNS medications), APIs (active pharmaceutical ingredients including vitamins, caffeine, and penicillins), and Formulation products (finished dosage forms). The portfolio includes innovative drugs like the National Class I new drug Butylphthalide (NBP) for stroke treatment, the world's first Mitoxantrone Hydrochloride Liposome Injection (Duoenda), and Copiktra (first PI3K inhibitor in China). CSPC also develops a diverse pipeline of approximately 300 projects including small molecule drugs, macromolecule biologics, and novel preparations targeting cancer, CNS, metabolic, and infectious diseases.

Differentiator

Problem solved

Functional benefit

Brands

• AlaMab Therapeutics: Subsidiary focusing on novel monoclonal antibody therapeutics for orphan and rare pediatric diseases, developed first-in-class antibody drugs targeting Connexin43 hemichannels for neurological injuries and bone cancers.
• Duoenda
• Kebituo

Products and services

• NBP (Butylphthalide) A proprietary innovative drug indicated for the treatment of acute ischemic stroke, sold to hospitals and clinical pharmacies in China.
• Duomeisu (Doxorubicin nano-liposome) Lipid nanoparticle formulation of doxorubicin for oncology, sold to hospitals and oncology treatment centers.
• Jinyouli (PD-1 monoclonal antibody) PD-1 monoclonal antibody used in oncology treatment, sold to hospitals and oncology centers.
• Anfulike (Anifrolumab) Monoclonal antibody indicated for immunology indications, sold to hospitals and immunology specialty centers.
• Beforezin (Netakimab) Anti-IL-17 monoclonal antibody for immunology indications, sold to hospitals and immunology specialty centers.
• Habaitake (Omalizumab biosimilar) Omalizumab biosimilar antibody for immunology indications, sold to hospitals and immunology specialty centers.
• Zabitoro (Tafamidis) Tafamidis formulation for the treatment of transthyretin amyloid cardiomyopathy, sold to hospitals and cardiology centers.
• Generic pharmaceutical portfolio Broad portfolio of generic pharmaceutical products across multiple therapeutic areas, sold to hospitals, distributors, and pharmacies in China.
• Active pharmaceutical ingredients (APIs) Active pharmaceutical ingredients produced in-house and supplied to other pharmaceutical companies as B2B inputs.

Quantifiable outcome

• First mitoxantrone nano-drug launched in the world with patent granted in 10+ countries
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• AstraZenecacoreStrategic or Co-development Partner · 30 January 2026CSPC entered into strategic collaboration and license agreement with AstraZeneca for the development of innovative long-acting peptide medicines.
• Harbour Biomed (Shanghai) Co., Ltd.coreStrategic or Co-development Partner · 10 October 2022CSPC entered into exclusive license agreement with Harbour Biomed to develop, manufacture and commercialize batoclimab (HBM9161) in Greater China. CSPC agreed to pay RMB150 million upfront, up to RMB50 million technology milestones, up to RMB400 million development/regulatory milestones, up to US$57.5 million sales milestones plus tiered royalties. Batoclimab is a fully human monoclonal antibody targeting FcRn for autoimmune diseases.
• Flame BiosciencescoreStrategic or Co-development Partner · 1 January 2021CSPC's subsidiary NovaRock Biotherapeutics entered into strategic cooperation and licensing agreement with Flame Biosciences for the antibody drug NBL-015, taking a critical step toward globalization.
• Various Domestic and Foreign Scientific Research InstitutescoreTechnology or Integration · 1 January 2019CSPC maintains ongoing cooperation and exchanges with domestic and foreign scientific research institutes, following development trends of advanced technology to supplement pipeline of products under development.
• University of TexascoreStrategic or Co-development Partner · 1 January 2017AlaMab Therapeutics, CSPC's strategic investment company, licensed two novel functional antibody drug candidates targeting Connexin43 hemichannels from University of Texas. The initial portfolio was built upon these novel antibodies targeting neurological injuries and malignant tumors.
• TevaminorStrategic or Co-development Partner · 1 January 2016CSPC signed overseas product technology licensing and commercialization cooperation agreement for high-end generic drugs with Teva.
• CitronminorStrategic or Co-development Partner · 1 January 2016CSPC signed overseas product technology licensing and commercialization cooperation agreement for high-end generic drugs with Citron.
• CasperminorStrategic or Co-development Partner · 1 January 2016CSPC signed overseas product technology licensing and commercialization cooperation agreement for high-end generic drugs with Casper.

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• AstraZeneca: Global biopharmaceutical major; CSPC's strategic partner on long-acting peptides (2026) and co-developer of Daiichi Sankyo ADC franchise. Comparable therapeutic area overlap in oncology, cardiovascular, and metabolic diseases.
• Sinopharm Group: China's largest pharmaceutical conglomerate with significant overlap in API manufacturing, drug distribution, and pharmaceutical preparation operations. Larger and more diversified but with comparable core product lines.
• Novo Nordisk: Global leader in diabetes care and GLP-1 receptor agonists (Ozempic, Wegovy). Directly comparable to CSPC's cardiometabolic pipeline ambitions; sets competitive benchmark for TG103 and semaglutide biosimilar.
• Eli Lilly: Global pharmaceutical major with strong diabetes/obesity (Mounjaro, Zepbound) and oncology franchises. Relevant as a major competitor in CSPC's targeted cardiometabolic and ADC categories.

Emerging players

• Innovent Biologics: Chinese biopharmaceutical company specializing in innovative biologics and ADCs (PD-1, biosimilars). Comparable to CSPC's biologics expansion strategy and competes in oncology and metabolic disease pipeline.
• Daiichi Sankyo: Japanese pharmaceutical major with leading ADC platform (Enhertu, datopotamab deruxtecan). Direct competitor in ADC oncology space where CSPC has built proprietary pipeline (SYS6043, SYS6002).

Direct peers

• Fosun Pharma: Chinese pharmaceutical conglomerate combining innovative R&D, generic manufacturing, and global distribution. Comparable pipeline diversification across oncology, CNS, and metabolic diseases, with international licensing activities.
• Shanghai Pharmaceuticals Holding: Major integrated Chinese pharmaceutical group with APIs, formulations, and innovative drug businesses. Comparable scale, geographic footprint, and product mix including antibiotics, cardiovascular and CNS medications.
• Jiangsu Hengrui Pharmaceuticals: Largest Chinese innovative pharmaceutical company with comparable pipeline of small molecule and biologic drugs, oncology focus, and global out-licensing strategy. Directly competes with CSPC in domestic Chinese market and increasingly in global markets.
• Hansoh Pharmaceutical: Leading Chinese innovative pharmaceutical company focused on oncology, CNS, and metabolic diseases. Comparable pipeline strategy, Class 1 innovative drugs, and increasing international licensing activities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/opus-pharmaceuticals-limited

Compliance24 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OPUS PHARMACEUTICALS LIMITED